Researchers compared patients over and under 75 years of age to evaluate the safety and efficacy of the SGLT2 inhibitor in an older population.
Veronica Hackethal, MD
Exercise may lower the risk of diabetes, metabolic syndrome, or CV events, but the relationship between exercise and insulin sensitivity is complex.
Researchers compared four different methods of estimating starting basal insulin infusion rates when transitioning to pump therapy. Which was best?
Researchers looked at fractures, fall-related adverse events, and volume depletion-related adverse events in over 10,000 people taking canagliflozin.
Evidence suggesting the cardiovascular protective effects of SGLT2 inhibitors is growing, yet one potential risk increased.
When looking to reduce gestational diabetes risk, do lifestyle interventions work? Is it better to focus on diet, exercise, or both?
New data suggest overly intensive blood pressure treatment in diabetics could lead to worse CV outcomes. How should you set goals for your patients?
A new study looks at the role of an SGLT2 inhibitor on cardiovascular outcomes in type 2 diabetes patients.
Whether used as monotherapy or dual therapy, is there an advantage to using one specific SGLT2 inhibitor over another?
Studies of cancer risks with diabetes have been comprised mostly of people with T2DM, leaving the links between cancer and T1DM relatively unknown.